Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Methadone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Methadone + DCV 3DAA FDC + BMS-791325 | EXPERIMENTAL | Methadone 40-120 mg tablet or solution orally once on Day 1 Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12 |
| Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325 | ACTIVE_COMPARATOR | Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1 Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12 |
| Name | Type | Description |
|---|---|---|
| Methadone | DRUG | - |
| DCV 3DAA FDC | DRUG | - |
| BMS-791325 | DRUG | - |
| Buprenorphine | DRUG | - |
| Naloxone | DRUG | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Subject must be on stable Methadone or Buprenorphine regimens for at least 28 days prior to screening Exclusion Criteria: * Subjects must be healthy except for history of M...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
Methadone is being studied for use in Hepatitis C as part of a Phase 1 clinical trial. The trial, NCT02045693, is a drug interaction study involving Methadone and Buprenorphine in healthy volunteers. It is an active-controlled, non-randomized study that has been completed with 32 participants in the United States.
Methadone is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting research on Methadone for the treatment of Hepatitis C, an infectious disease. The drug is a small molecule therapeutic currently in Phase 1 clinical development.
Methadone is in Phase 1 clinical development for Hepatitis C. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial, NCT02045693, has been completed, and it involved 32 participants. The study was conducted in the United States and included healthy volunteers.
Methadone has one completed clinical trial, NCT02045693, titled "Drug Interaction & Methadone & Buprenorphine." This Phase 1 study enrolled 32 participants with Hepatitis C and was conducted in the United States. The trial was active-controlled and included healthy volunteers aged 18 years and older.
No, Methadone is not the same as Buprenorphine. They are distinct drugs. However, they are being studied together in a clinical trial, NCT02045693, to assess drug interactions. This Phase 1 study is investigating their combined effects in the context of Hepatitis C treatment.